Evidence map›Paper›PMID 29603363›Full record

ArticleAmerican journal of hematology2018

Transfusion-related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: A retrospective survey by the international sickle cell disease observatory.

Jean-Antoine Ribeil, Myriam Labopin, Aurélie Stanislas, Benjamin Deloison, Delphine Lemercier, Anoosha Habibi, Souha Albinni, Caroline Charlier, Olivier Lortholary, François Lefrere and 10 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in American journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Acute pain episodes, acute chest syndrome, and pulmonary thromboembolism in pregnancy.Hematology. American Society of Hematology. Education Program · 2022
    Pooled it
  3. Proactive management to improve outcomes of high-risk pregnancy in people with sickle cell disease.Hematology. American Society of Hematology. Education Program · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Managing pregnancy in patients with sickle cell disease from a transfusion perspective.Hematology. American Society of Hematology. Education Program · 2023
    Article
  8. Complications in pregnant women with sickle cell disease.Hematology. American Society of Hematology. Education Program · 2019
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Jean-Antoine RibeilBiotherapy Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID 0000-0002-4549-4783
Myriam LabopinClinical Hematology and Cellular Therapy Department, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, France - INSERM UMRs 938, Pierre et Marie Curie University (UPMC, Paris VI), Paris, France.
Aurélie StanislasBiotherapy Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Benjamin DeloisonDepartment of Obstetrics and Fetal Medicine, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Delphine LemercierDepartment of Obstetrics and Fetal Medicine, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Anoosha HabibiReference Center for Sickle Cell Disease, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France.
Souha AlbinniNecker Children's Hospital, French Blood Establishment - Ile de France, Paris, France.
Caroline CharlierNecker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Necker Pasteur Center for Infectious Diseases and Tropical Medicine, Paris, France.
Olivier LortholaryImagine Institute, Paris, France.
François LefrereBiotherapy Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Mariane De MontalembertReference Centre for Sickle Cell Disease, Pediatric Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Stéphane BlancheUnit of Pediatric Immunology and Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Frédéric GalactérosReference Center for Sickle Cell Disease, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France.
Jean-Marc TréluyerParis Descartes University, Paris, France.
Eliane GluckmanSaint-Louis Hospital, Paris, France and Monaco Scientific Center, Eurocord Monacord International Observatory on Sickle Cell Disease, Monaco.
Yves VilleDepartment of Obstetrics and Fetal Medicine, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Laure JosephBiotherapy Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Marianne DelvilleBiotherapy Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Alexandra BenachiDepartment of Obstetrics and Gynecology and Reproductive Medicine, Antoine Béclère Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Sud, Clamart, France.
Marina CavazzanaBiotherapy Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Assistance Publique – Hôpitaux de Paris · FRInserm · FRDélégation Paris 5 · FRHôpital Necker-Enfants Malades · FRInternational University of Monaco · MCUniversité Paris-Sud · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sickle cell disease (SCD) in pregnancy can be associated with adverse maternal and perinatal outcomes. Furthermore, complications of SCD can be aggravated by pregnancy. Optimal prenatal care aims to decrease the occurrence of maternal and fetal complications. A retrospective, French, two-center study compared two care strategies for pregnant women with SCD over two time periods. In the first study period (2005-2010), the women were systematically offered prophylactic transfusions. In the second study period (2011-2014), a targeted transfusion strategy was applied whenever possible, and home-based prophylactic nocturnal oxygen therapy was offered to all the pregnant women. The two periods did not differ significantly in terms of the incidence of vaso-occlusive events. Maternal mortality, perinatal mortality, and obstetric complication rates were also similar in the two periods, as was the incidence of post-transfusion complications (6.1% in 2005-2010 and 1.3% in 2011-2014, P = .15), although no de novo alloimmunizations or delayed hemolysis transfusion reactions were observed in the second period. The results of this preliminary, retrospective study indicate that targeted transfusion plus home-based prophylactic nocturnal oxygen therapy is safe and may decrease transfusion requirements and transfusion-associated complications.

Indexed as

AdolescentAdultArterial Occlusive DiseasesBlood TransfusionFemaleFranceHumansOxygenPregnancyPregnancy Complications, HematologicPremedicationRetrospective StudiesSurveys and QuestionnairesTransfusion ReactionYoung AdultOxygen

Identifiers

PMID29603363
PMCPMC6001537
OpenAlexW2795279141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.